Executive Revenue Leadership for
Scaling Healthcare SaaS Companies

A growth-stage healthcare SaaS company providing care coordination software to regional health systems engaged KORE Strategies after 18 months of stagnant new logo growth. The product was strong — existing customers renewed at over 90 percent and NPS scores were among the best in their category. But the new business engine wasn’t working.

Average sales cycle: 14 months. Close rate on qualified opportunities: below 20 percent. Two AEs hired over the prior year had produced a combined two new logos. The board was asking questions the CEO didn’t have good answers for.

The assumption in the room was that the company needed more pipeline — more outbound activity, more SDR capacity, more marketing spend. Our assessment told a different story.

After a four-week revenue audit — including CRM analysis, win/loss deal reviews, rep call shadowing, and interviews with three existing health system customers — four root causes emerged:

• Deals were single-threaded. In 80 percent of active opportunities, the rep had a primary relationship with one stakeholder — almost always a clinical champion at the department or service line level. Finance, IT, and operational leadership had not been engaged. Deals were advancing through clinical evaluation and dying when they hit procurement, IT security review, or CFO scrutiny — because nobody had built those relationships in advance.
• The pipeline was significantly overstated. Opportunities were being created in the CRM after a demo regardless of qualification. Of 34 active opportunities, fewer than 12 had a confirmed economic buyer or a documented business problem. The pipeline looked healthy. It wasn’t.
• Discovery was shallow and inconsistent. Each rep was running discovery differently. Some were getting to business impact and stakeholder landscape in the first meeting. Others were leading with product features. There was no shared framework, which meant management couldn’t coach consistently and new reps had no model to follow.
• The playbook didn’t reflect healthcare selling realities. The existing playbook had been adapted from a generic B2B SaaS template. It had no guidance on navigating EHR integration conversations with IT Directors, no framework for the BAA and security review stage, and no stakeholder-specific messaging for the CFO or compliance officer. Reps were improvising on the most important conversations in the deal.

KORE Strategies executed a 90-day engagement across four parallel workstreams:

• Healthcare-specific playbook rebuild. We built a new playbook from the ground up — starting with interviews of the company’s six best-fit customers to validate ICP, buyer personas, and purchase triggers. The playbook included stakeholder-specific value narratives for clinical, operational, financial, IT, and compliance roles; a healthcare discovery framework; and an objection library built around the specific resistance patterns the team was actually encountering.
• Multi-threading framework. We trained reps on stakeholder mapping in the first two discovery calls and built engagement sequences for IT Directors and CFOs that could run in parallel with the clinical evaluation. We created a health system org chart tool that helped reps identify who else needed to say yes before a deal could close.
• Pipeline qualification overhaul. We defined three mandatory qualification criteria — confirmed economic buyer, documented business problem in the buyer’s words, and a defined decision timeline — and ran a full pipeline audit. Twelve of 34 opportunities were disqualified or moved to nurture. The pipeline shrank. The conversations about the remaining deals became much more productive.
• Deal review cadence. We installed a weekly 60-minute deal review with the CEO and VP of Sales, using a structured format that required reps to articulate the full stakeholder map, IT and legal status, next buyer actions, and biggest deal risk on every active opportunity. This single change had more impact on forecast accuracy than any other intervention.

Within two full quarters of the engagement:

• Average sales cycle dropped from 14 months to 9 months — a 35 percent reduction — primarily driven by earlier multi-stakeholder engagement that prevented late-stage IT and procurement surprises.
• Close rate on qualified opportunities increased from 18 percent to 34 percent.
• Pipeline size decreased by 35 percent. Revenue increased.
• Three enterprise health system deals that had been stalled for six-plus months were unblocked through direct CFO and IT Director engagement facilitated by the new multi-threading framework.
• Forecast accuracy improved from roughly 50 percent to over 80 percent within one quarter of installing the deal review cadence.
• New rep ramp time dropped from nine months to five months after the new playbook and onboarding curriculum were deployed.

‘We thought we needed more pipeline. What we actually needed was a process that worked. Once we fixed how we were qualifying and how we were navigating the buying committee, the deals we already had were more than enough to hit our targets. And for the first time, I actually trusted the forecast.’

The improvements in this engagement came entirely from fixing the revenue infrastructure — not from adding headcount, changing the product, or increasing marketing spend. The team that was struggling at 18 percent close rates and 14-month cycles was the same team that delivered 34 percent close rates and 9-month cycles six months later. The difference was the system they were working inside.

If your healthcare SaaS company has strong product-market fit but inconsistent new logo growth, the answer is almost never more pipeline. It’s a better process for the pipeline you have.